The aim in establishing a Clinical Oncology Program at Geisinger Medical Center is to channel a large number of patients with cancer into quality research treatment protocols, taking full advantage of the tertiary nature of the center (accrues rare cancers and is able to provide state-of-the-art care and facilities). Aspects of the Geisinger system that are advantageous include its large cancer patient population (1400 new pts/yr.), its excellent medical record system with unit patient charts, the presence of all needed treatment facilities and specialists under one roof, with an organized cancer center in place, and its past record of proven commitment to clinical research and capabilities to manage protocol data effectively. All of the headquarters and data management staff required for successful CCOPS operation are already in place, all doing their planned functions. The nature of the planned research participation is multimodal, as well as multidisciplinary. Our CCOPS will feature a multidisciplinary group--the Mid Atlantic Oncology Program--as its primary base with specialty bases to include a radiation therapy group--The RTOG--, as well as a pediatric base--the Children's Cancer Study Group. We feel this multifaceted selection of research bases definitely enhances multimodality cooperation here within the CCOPS, as well as providing an unusual balance for a community program. The referral area of the Geisinger Medical Center is such that changes in care here have a ripple effect throughout a wide area. The medical center is the recognized care leader in this part of Pennsylvania, having been designated one of only four tertiary care centers for the entire state. As the application will make clear, we have also felt the responsibility to play a leadership role in education, cancer control and administrative assistance to the various community hospitals to which we relate. Geisinger has grown into a system of health care in recent years, now owning and operating a new large hospital in the Wilkes-Barre-Scranton area, running a multispecialty medical group in the same area, owning another multispecialty group 100 miles to our west, owning and operating ER's and other facilities in the region. The beneficial effect of a CCOPS in such a system will cover a large area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035448-03
Application #
3557806
Study Section
(SRC)
Project Start
1983-09-15
Project End
1987-05-31
Budget Start
1985-09-01
Budget End
1987-05-31
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Geisinger Medical Center
Department
Type
DUNS #
City
Danville
State
PA
Country
United States
Zip Code
17822
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005
Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92
Patel, Krishna; Foster, Nathan R; Farrell, Ann et al. (2013) Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature. J Cancer Educ 28:770-6
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92

Showing the most recent 10 out of 115 publications